Antipsychotic treatment of schizophrenia: An update

Asian Journal of Psychiatry

Volumn 11, Issue , 2014, Pages 3-7

  Bruijnzeel, Dawn ^a   Suryadevara, Uma ^a   Tandon, Rajiv ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic; Effectiveness; Guideline; Review; Schizophrenia; Treatment

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COGNITION; COGNITIVE THERAPY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPOTENSION; LIFESPAN; LOW RISK PATIENT; MEDICAL DECISION MAKING; METABOLIC DISORDER; MONOTHERAPY; MORTALITY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; REFRACTORY PERIOD; RELAPSE; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL ADAPTATION; SOCIAL STATUS; SOCIAL SUPPORT; STANDARDIZATION; TRAINING; TREATMENT DURATION; UROGENITAL TRACT DISEASE;

ANTIPSYCHOTIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SCHIZOPHRENIA;

EID: 84911995831     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2014.08.002     Document Type: Review

References (61)

1. Barch D.M., Bustillo J., Gaebel W., et al. Logic and justification for dimensional assessment of symptoms and related phenomena in psychosis: relevance to DSM-5. Schizophr. Res. 2013, 150:15-20.
2. Bollini P., Pampallona S., Nieddu S., et al. Indicators of conformance with guidelines of schizophrenia treatment in mental health services. Psychiatr. Serv. 2008, 59:782-791.
3. Bonham C., Abbott C. Are second-generation antipsychotics a distinct class?. J. Psychiatr. Pract. 2008, 14:225-237.
4. Buchanan R.W., Kreyenbuhl J., Kelly D.L., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
5. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
6. Davidson M., Galderisi S., Weiser M., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 2009, 166:675-682.
7. Derks E.M., Fleischhacker W.W., Boter H., et al. Antipsychotic drug treatment in first-episode psychosis. J. Clin. Psychopharmacol. 2010, 30:176-180.
8. Emsley R., Rabinowitz J., Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 2006, 163:743-745.
9. Fischer-Barnicol D., Lanquillon S., Haen E., et al. Typical and atypical antipsychotics - the misleading dichotomy. Neuropsychobiology 2008, 57:80-87.
10. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 231:1371-1376.
11. Gilbert P., Harris M.J., McAdams L.A., et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch. Gen. Psychiatry 1995, 52:173-188.
12. Heckers S., Tandon R., Bustillo J. Catatonia in the DSM - shall we move or not?. Schizophr. Bull. 2010, 36:205-207.
13. Heckers S., Barch D.M., Bustillo J., et al. Structure of the psychotic disorders classification in DSM-5. Schizophr. Res. 2013, 150:11-14.
14. Hill S.K., Bishop J.R., Palumbo D., Sweeney J.A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev. Neurother. 2010, 10:43-57.
15. Hugenholtz G.W., Heerdink R., Stolker J.J., et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J. Clin. Psychiatry 2006, 67:897-903.
16. Johnstone E.C., Crow T.J., Frith C.D., et al. Mechanism of antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978, 1:848-851.
17. Kahn R.S., Fleischhacker W.W., Boter H., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008, 371:1085-1097.
18. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
19. Kapur S., Remington G. Dopamine D2 receptors and their role in antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001, 50:873-883.
20. Keefe R.S.E., Bilder R.M., Davis S.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64:633-647.
21. Keshavan M.S., Tandon R., Boutros N., Nasrallah H.A. Schizophrenia, "Just the Facts". What we know in 2008. Part 3: Neurobiology. Schizophr. Res. 2008, 106:89-107.
22. Kinon B.J., Chen L., Ascher-Svanum H., et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590.
23. Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B. The schizophrenia patient outcomes research team (PORT) recommendations, 2009. Schizophr. Bull. 2010, 36:94-103.
24. Leucht S., Corves C., Arbter D., et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
25. Leucht S., Arbter D., Engel R.R., et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14:429-447.
26. Leucht S., Komossa K., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166:152-163.
27. Leucht S., Tardy M., Komossa K., et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379:2063-2071.
28. Leucht S., Cipriani A., Spinelli L., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis. Lancet 2013, 382:951-962.
29. Lewis S.W., Barnes T.R., Davies L., et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32:715-723.
30. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1233.
31. Marder S.R., Essock S.M., Miller A.M., et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 2004, 161:1334-1349.
32. McEvoy J.P., Lieberman J.A., Stroup J.P., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
33. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand. 2007, 115:260-267.
34. Nasrallah H.A., Targum S.D., Tandon R., et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 2005, 56:273-282.
35. Remington G., Foussias G., Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
36. Salimi K., Jarskog L.F., Lieberman J.A. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 2009, 23:837-855.
37. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427. Schizophrenia Working Group of the Psychiatric Genomics Consortium.
38. Smith M., Hopkins D., Peveler R.C., et al. First- v. second- generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008, 196:406-411.
39. Swartz M.S., Perkins D.O., Stroup T.S., et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164:428-436.
40. Tandon R. Antipsychotics in the treatment of schizophrenia. J. Clin. Psychiatry 2011, 72:1-8.
41. Tandon R. The nosology of schizophrenia: towards DSM-5 and ICD-11. Psychiatr. Clin. N. Am. 2012, 35:555-569.
42. Tandon R., Carpenter W.T. DSM-5 status of psychotic disorders. Schizophr. Bull. 2012, 38:369-370.
43. Tandon R., Halbreich U. The second-generation 'atypical' antipsychotics: Similar improved efficacy but different neuroendocrine side-effects. Psychoneuroendocrinology 2003, 28:1-7.
44. Tandon R., Maj M. Nosological status and definition of schizophrenia. Asian J. Psychiatry 2008, 1:22-27.
45. Tandon R., Nasrallah H.A. Subjecting meta-analyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics. The author's reply. Arch. Gen. Psychiatry 2006, 63:935-939.
46. Tandon R., DeQuardo J.R., Taylor S.F., et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr. Res. 2000, 45:191-201.
47. Tandon R., Jibson M.D. Comparing efficacy of first-line atypical antipsychotics. No evidence of differential efficacy. Int. J. Psychiatry Clin. Pract. 2005, 9:204-212.
48. Tandon R., Targum S.D., Nasrallah H.A., Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 2006, 12:348-363.
49. Tandon R., DeVellis R.F., Han J., et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res. 2006, 136:211-221.
50. Tandon R., Keshavan M.S., Nasrallah A. Schizophrenia, "Just the Facts". What we know in 2008. Part 1: Overview. Schizophr. Res. 2008, 100:4-19.
51. Tandon R., Moller H.-J., Belmaker R.H., et al. World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 2008, 100:20-38.
52. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "Just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110:1-23.
53. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "Just the facts" 5. Treatment and prevention. Schizophr. Res. 2010, 122:1-23.
54. Tandon R., Gaebel W., Barch D., et al. Schizophrenia in the DSM-5. Schizophr. Res. 2013, 150:3-10.
55. Tandon R., Heckers S., Bustillo J., et al. Catatonia in the DSM-5. Schizophr. Res. 2013, 150:26-30.
56. Tapp A., Kilzieh N., Wood A.E., et al. Depression in patients with schizophrenia during an acute psychotic episode. Compr. Psychiatry 2001, 42:314-318.
57. Torres-Gonzalez F., Ibanez-Casas I., Saldivia S., et al. Unmet needs in the management of schizophrenia. Neuropsychiatr. Dis. Treat. 2014, 10:97-110.
58. Tsuang M.T., van Os J., Tandon R., et al. Attenuated psychosis syndrome in DSM-5. Schizophr. Res. 2013, 15:31-35.
59. Voruganti L., Awad A.G. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 2004, 171:121-132.
60. Weiden P.J. EPS profiles: the atypical antipsychotics are not all the same. J. Psychiatric Pract. 2007, 13:13-24.
61. Wunderink L., Nieboer R.M., Wiersma D., et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance strategy. JAMA Psychiatry 2013, 70:913-920.